| John Clark Mayberry, MD | |
|
1906 Fairview Ave Ste 130, Caldwell, ID 83605-5433 | |
| (208) 453-4260 | |
| (844) 213-3678 |
| Full Name | John Clark Mayberry |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 38 Years |
| Location | 1906 Fairview Ave Ste 130, Caldwell, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528074077 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | M-12108 (Idaho) | Secondary |
| 208600000X | Surgery | M-12108 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Valley Medical Center | Caldwell, ID | Hospital |
| Entity Name | St Lukes Clinic - Wood River Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972891604 PECOS PAC ID: 3173783818 Enrollment ID: O20120404000474 |
News Archive
A new study supports the efficacy of smartphone fitness apps and wearable activity trackers at elevating levels of physical activity.
Great things come in small packages, or at least that's what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.
Facial expressions convey strong cues for someone's emotional state and the ability to interpret these cues is crucial in social interaction. This ability is known to be compromised in many psychiatric and neurological disorders, such as social anxiety or Korsakoff's syndrome.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 1 days ago
| Entity Name | Idahosurgeons Net Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295237022 PECOS PAC ID: 4183975865 Enrollment ID: O20210825001480 |
News Archive
A new study supports the efficacy of smartphone fitness apps and wearable activity trackers at elevating levels of physical activity.
Great things come in small packages, or at least that's what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.
Facial expressions convey strong cues for someone's emotional state and the ability to interpret these cues is crucial in social interaction. This ability is known to be compromised in many psychiatric and neurological disorders, such as social anxiety or Korsakoff's syndrome.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Clark Mayberry, MD Po Box 1074, Caldwell, ID 83606-1074 Ph: (208) 453-4260 | John Clark Mayberry, MD 1906 Fairview Ave Ste 130, Caldwell, ID 83605-5433 Ph: (208) 453-4260 |
News Archive
A new study supports the efficacy of smartphone fitness apps and wearable activity trackers at elevating levels of physical activity.
Great things come in small packages, or at least that's what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.
Facial expressions convey strong cues for someone's emotional state and the ability to interpret these cues is crucial in social interaction. This ability is known to be compromised in many psychiatric and neurological disorders, such as social anxiety or Korsakoff's syndrome.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 1 days ago
Dr. Ryan W. Hardy, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Elm St Ste 350, Caldwell, ID 83605 Phone: 208-459-0028 | |
Dr. Daniel Paul Gay, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 404 Elm Street, Caldwell, ID 83605 Phone: 208-459-0028 Fax: 208-459-0380 | |
Jon Moore Agee, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 404 E Elm St, Caldwell, ID 83605 Phone: 208-459-0028 Fax: 208-459-0380 | |
Dr. Adam D. Bell, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Elm St Ste 350, Caldwell, ID 83605 Phone: 208-459-0028 Fax: 208-504-4311 | |
Dr. M Whitney Parnell, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Elm St Ste 350, Caldwell, ID 83605 Phone: 208-459-0028 |